Genmab A/S (NASDAQ:GMAB) Price Target Lowered to $39.00 at HC Wainwright

Genmab A/S (NASDAQ:GMAB) had its price objective trimmed by HC Wainwright from $41.00 to $39.00 in a research note released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently issued reports on GMAB. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a research note on Tuesday, September 23rd. Johnson Rice reiterated a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research note on Saturday, November 22nd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $39.25.

Genmab A/S Stock Performance

Shares of GMAB opened at $31.33 on Tuesday. The stock has a market capitalization of $20.13 billion, a P/E ratio of 13.33, a P/E/G ratio of 2.12 and a beta of 0.90. Genmab A/S has a 1 year low of $17.24 and a 1 year high of $35.43. The company’s fifty day moving average is $31.99 and its two-hundred day moving average is $28.48.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently added to or reduced their stakes in the business. Founders Capital Management lifted its holdings in shares of Genmab A/S by 40.0% in the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Genmab A/S by 11.3% during the 3rd quarter. Parallel Advisors LLC now owns 4,139 shares of the company’s stock worth $127,000 after purchasing an additional 419 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in Genmab A/S by 29.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock valued at $57,000 after buying an additional 440 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares in the last quarter. Finally, Orion Porfolio Solutions LLC grew its holdings in Genmab A/S by 2.3% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock valued at $604,000 after buying an additional 441 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.